Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Tyratech soars as it slashes losses

The company is treading a fine line between conserving cash and capitalising on growing demand for its Vamousse head lice product
Head lice
"Looking to 2018, we have hopes of further increasing the distribution for our Vamousse range of products in the US"

Tyratech, Inc. (LON:TYR LON:TYRU) saw its shares gain today after the pest control technology firm said its products outperformed a recovering US head lice market in the first half of 2017.

In late morning trading, Tyratech shares were almost 4.9%, or 0.05p higher at 1.08p.

In a statement, the AIM-listed company said like-for-like sales of its Vamousse head lice product are outstripping the market in the US, contributing to a handy increase in first half revenues to US$4.3mln from US$4.1mln in the first half of last year.

WATCH: Tyratech boss focused on unlocking full value of the business

Management took the decision to focus is marketing and commercial resources supporting Vamousse on the US market, and reduce its commitment to other markets – most notably the UK, where a slow-down in Vamousse sales has been seen as a consequence.

READ: Tyratech gets major boost as global group licenses pest control tech

The company, still in the growth stage of its development, slashed losses from operation to US$711,000 from US$1.52mln the previous year.

Loss before tax narrowed dramatically to £254,000 from a loss the year before of £1.52mln, helped by a £456,000 gain on the sale of intellectual property to Envance Technologies.

The sale to Envance has also provided the company with an upfront payment of $500,000, received subsequent to the half year-end. Tyratech ended the reporting period with cash and cash equivalents of US$1.3mln, down from US$1.8mln at the end of 2016.

Losses to narrow

Chief executive Bruno Jactel said the company should show a significant reduction of its net losses over the full year when compared with 2016.

“This will be achieved through a combination of sales growth and tight control of operational expenses, together with the sale of IP to Envance,” Jactel said.

“Looking to 2018, we have hopes of further increasing the distribution for our Vamousse range of products in the US. We also note with great interest the recent issues regarding the use of unauthorized insecticides to control red mites in poultry facilities in Europe and the resulting effects on egg production. We believe that our pesticide-free products deliver competitive efficacy against the red mite, which is a major problem in Europe. We have already initiated field studies in France and plan to progress this opportunity as quickly as resources and the regulatory situation permit,” he added.

Non-executive chairman José Barella said the company’s previously announced strategic review is still in progress.

“Our focus remains to unlock the full value of the business for shareholders. The process is progressing well and we intend to provide a full update to the market once we have reached concrete conclusions as to the best outcome for all our shareholders," Bartella said.

 -- Adds share price, video link --

View full TYR profile View Profile

TyraTech, Inc. Timeline

Big Picture
September 12 2017

Related Articles

TyraTech boffin
September 12 2017
The company expects to slash losses in 2017 as it constrains costs and grows sales of Vamousse
Downhill skiier
May 03 2017
In an interview, CEO Giulio Cesareo said: "Last year was a very important time for Directa Plus … an exceptional year for a lot of positive reasons, but it was also a very important learning period for the group”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use